LIANY — LianBio

OTC · Health Care · Pharmaceuticals · CIK 1831283 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2022 0 0 -24,549,000 -21,897,000 319,960,000 79,221,000 26,313,000
Dec 2021 0 0 -13,544,000 -13,112,000 426,343,000 228,182,000 39,007,000

Annual Trend (SEC EDGAR, last 1y)

Revenues vs Net Income (last 1y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2022 0 -125,353,000 -110,290,000 319,960,000 26,313,000 -99,185,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-35,009,000
OpCashFlow TTM
$0
Assets (Latest)
$319,960,000
Forward EPS
$-0.36

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $949.47B $1064.74
JNJ JOHNSON & JOHNSON $554.09B $230.18
ABBV AbbVie Inc. $376.54B $213.12
MRK Merck & Co., Inc. $295.69B $119.72
AZN ASTRAZENECA PLC $290.30B $187.19

Recent Insider Activity

No insider activity indexed for this ticker.